Pipeline Overview
Symphogen’s most advanced drug candidate, Sym004, is currently being investigated in clinical studies in multiple cancer indications. Most progressed is a fully enrolled Phase 2b study in 254 patients with metastatic colorectal cancer (mCRC) and with acquired resistance to anti-EGFR antibody therapies, which is being conducted in the USA and Europe. Positive efficacy clinical findings from a previous study of Sym004 in the same patient population were published for the first time in the peer-reviewed journal, Cancer Discovery, in June 2015. Two additional drug candidates Sym015 (anti-MET) and Sym013 (anti-pan-HER) are expected to enter the clinic during 2016. Symphogen has built an innovative portfolio of early-stage immuno-oncology programs based on the company’s expertise in this field and its productive technology suite – capable of identifying, selecting, and manufacturing therapeutic antibodies and antibody mixtures. In early 2016 this resulted in a broad strategic collaboration with the US-based global biopharmaceutical Company, Baxalta, to advance novel therapeutics against six immuno-oncology targets. This collaboration was designed to build upon the rapidly expanding field of immunological checkpoint blockade which offers patients with improved efficacy in fighting a variety of cancers.”
For additional information, please contact:
Kirsten Drejer
Chief Executive Officer
Phone: + 45 22 10 99 59
E-mail: kd@symphogen.com
Martin Olin
Chief Financial Officer
Phone: + 45 40 21 85 32
E-mail: mol@symphogen.com
Consilium Strategic Communications
Mary-Jane Elliott, Amber Fennell, Lindsey Neville
Phone: +44 20 3709 5700
E-mail: symphogen@consilium-comms.com
Annes Associates
Shari Annes
Phone: 650-888-0902
E-mail: sannes@annesassociates.com